Doctor profile · Federal record

Dr. William Surbeck, M.D.

Rheumatology Physician (CMS: Rheumatology) · Tulsa, OK

  • NPI 1154382711
  • Accepts Medicare
  • MIPS 54.8 / 100 · 2023
  • 38 yrs in practice
  • Male
  • Group practice
  • No sanctions

Practice & contact

NPPES Updated May 11, 2026
Primary practice
4812 S 109Th East Ave, Ste. 200
Tulsa, OK 741465822
(918) 236-4567
fax (918) 236-4578

Credentials & registration

NPPES · NUCC
NPI registered
March 2006 — 20 yrs on file
Profile last updated
September 18, 2012
Year of graduation
1988 — 38 yrs since
Specialty taxonomy
207RR0500X — NUCC code
State license (1)
Oklahoma #16971
Medicaid
OK #100136560A

Federal sanctions & exclusions

OIG LEIE Updated May 11, 2026

No sanctions, exclusions or revocations on file

Checked against OIG LEIE on NPI 1154382711. Last verified May 11, 2026.

Medicare procedures · 2023

Top services delivered

CMS Provider Utilization
Total services
150,382
Distinct HCPCS
10
Medicare allowed
$2,246,277
HCPCS Description Services Patients Avg allowed
J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) 93,200 28 $5
J1602 Injection, golimumab, 1 mg, for intravenous use 27,050 35 $13
J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) 12,275 22 $42
J9312 Injection, rituximab, 10 mg 5,460 18 $77
J1745 Injection, infliximab, excludes biosimilar, 10 mg 5,430 19 $33
J0897 Injection, denosumab, 1 mg 3,840 36 $23
99214 Established patient office or other outpatient visit, 30-39 minutes 1,194 514 $118
96372 Injection of drug or substance under skin or into muscle 556 82 $13
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less 335 60 $57
96413 Administration of chemotherapy into vein, 1 hour or less 287 58 $113

In context: peer comparison

Among 2 peers in this city , average services per provider: 7,163. This provider delivers 21× the peer median.

Open Payments

Industry payments received

CMS Open Payments
All-time total
$2,904
Transactions
152
Manufacturers
14
Payer (manufacturer) Industry Txns Amount
Amgen Inc. 46 $842.65
ABBVIE INC. 25 $516.05
UCB, Inc. 21 $429.92
Janssen Biotech, Inc. 9 $248.01
Novartis Pharmaceuticals Corporation 11 $165.16
GlaxoSmithKline, LLC. 9 $156.25
PFIZER INC. 10 $136.63
Genentech USA, Inc. 5 $97.33
Aurinia Pharma U.S., Inc. 5 $96.39
AstraZeneca Pharmaceuticals LP 4 $86.38
Lilly USA, LLC 3 $56.34
Sandoz Inc. 2 $39.61
E.R. Squibb & Sons, L.L.C. 1 $19.64
SCILEX PHARMACEUTICALS INC. 1 $14.04

By nature of payment

Food and Beverage
$2,805
Education
$99

Medicare Part D · 2023

Top prescriptions

CMS Part D Prescriber
Total claims
4,589
Patients
878
Total drug cost
$3,426,679
Drug Type Claims Patients Total cost
Methotrexate (Methotrexate Sodium) Brand 1,136 216 $49,307
Hydroxychloroquine Sulfate Generic 1,020 225 $65,809
Prednisone Generic 607 119 $4,975
Leflunomide Generic 277 56 $23,226
Humira(Cf) Pen (Adalimumab) Brand 208 20 $1,924,173
Tramadol Hcl Generic 198 35 $2,196
Gabapentin Generic 195 42 $2,838
Enbrel Sureclick (Etanercept) Brand 174 19 $1,337,133
Meloxicam Generic 131 28 $994
Leucovorin Calcium Generic 125 22 $1,131

Frequently asked questions

Auto-generated from federal data
What is Dr. William Surbeck's medical specialty?
Dr. William Surbeck practices Rheumatology Physician in Tulsa, OK.
Where does Dr. William Surbeck practice?
Dr. William Surbeck practices at 4812 S 109Th East Ave, Tulsa, OK 741465822. Office phone: 9182364567.
What is Dr. William Surbeck's NPI?
Dr. William Surbeck's National Provider Identifier (NPI) is 1154382711, issued by NPPES.
Does Dr. William Surbeck accept Medicare assignment?
Yes. Dr. William Surbeck accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. William Surbeck commonly perform?
Top Medicare-reported procedures in 2023: Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS J0717); Injection, golimumab, 1 mg, for intravenous use (HCPCS J1602); Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS J0129). Source: CMS Medicare Physician & Other Practitioners file.